Antibiotic resistance is the ability of bacteria to survive or continue multiplying when exposed to an antibiotic that would normally inhibit or kill susceptible bacteria. It is a property of bacteria rather than a condition in which a person's body becomes resistant to an antibiotic. This distinction is important: if a bacterial strain is resistant to a particular drug, increasing exposure to that drug does not necessarily make the bacterium susceptible.
Resistance can be intrinsic, meaning a species naturally possesses characteristics that make a particular antibiotic ineffective, or acquired, meaning a previously susceptible bacterial population gains resistance through genetic change. Resistance may affect one antibiotic, several related antibiotics or multiple unrelated classes, depending on the mechanisms involved. Multidrug-resistant bacteria are resistant to several antimicrobial categories, while extensively drug-resistant and pan-drug-resistant terminology is used in specific clinical and microbiological contexts when resistance becomes broader. Antibiotic resistance is a normal evolutionary phenomenon, but human antibiotic use creates powerful selection pressures that can accelerate its emergence, persistence and spread.
Bacterial resistance operates through molecular mechanisms that prevent an antibiotic from reaching or affecting its target. One mechanism is enzymatic inactivation, in which bacteria produce enzymes that chemically modify or destroy the antibiotic. Beta-lactamases, for example, can hydrolyse the beta-lactam ring of many penicillins and related drugs; extended-spectrum beta-lactamases can confer resistance to a broader range of beta-lactam antibiotics. Another mechanism is modification of the antibiotic's target.
A bacterium can alter the molecular structure to which a drug normally binds, reducing drug affinity while retaining enough biological function for survival. Resistance can also result from reduced permeability, increased active efflux of the antibiotic from the cell, metabolic bypass or protection of the antibiotic's target. These mechanisms may occur alone or in combination. A bacterium that simultaneously reduces drug entry, pumps drugs out and modifies a target can be considerably harder to treat than one possessing only a single resistance mechanism.
Resistance genes can be carried in bacterial chromosomes or on mobile genetic elements such as plasmids, transposons and integrons. Plasmids are particularly important because some can move between bacteria and carry multiple resistance genes together. Horizontal gene transfer allows bacteria to acquire genetic information from organisms other than their direct parent, including through conjugation, transformation and transduction.
Conjugation commonly involves transfer of DNA between bacterial cells through cell-to-cell contact; transformation involves uptake of free DNA from the environment; transduction involves bacteriophages transferring bacterial genetic material. These processes mean that resistance does not have to arise independently in every bacterial lineage. A resistance determinant that emerges in one organism can potentially spread through bacterial populations or between related and, in some circumstances, more distantly related species. This capacity for genetic exchange is a major reason antibiotic resistance is considered both an evolutionary and an ecological problem rather than simply an issue of individual treatment failure.
Antibiotic resistance is not synonymous with treatment failure in every clinical circumstance. A resistant laboratory isolate may still be treatable with another antibiotic to which it remains susceptible, and susceptibility results help clinicians identify potentially effective options. Conversely, a bacterium can appear susceptible in laboratory testing but treatment can still fail because of inadequate drug concentration at the infection site, poor adherence, an abscess requiring drainage, an incorrect diagnosis or an impaired host response.
Laboratory susceptibility testing measures how bacteria respond to particular antimicrobial concentrations under defined conditions; clinical effectiveness depends on pharmacokinetics, pharmacodynamics, infection location, immune status, dosing and other factors. The minimum inhibitory concentration, or MIC, is one important laboratory measurement describing the lowest concentration of an antimicrobial that prevents visible bacterial growth under specified testing conditions. Breakpoints are then used to categorise isolates as susceptible, intermediate or resistant according to established interpretive standards.
Resistance occurs across many bacterial species and antibiotic classes, making it a broad public-health issue. Examples include methicillin-resistant Staphylococcus aureus, commonly abbreviated MRSA, and strains of Enterobacterales producing extended-spectrum beta-lactamases or carbapenemases. Vancomycin-resistant enterococci are another clinically important resistant group. Drug-resistant tuberculosis presents a particularly serious challenge because treatment may require multiple drugs over prolonged periods, and resistance to key agents can substantially narrow therapeutic options.
Resistance is also important in organisms causing common community infections, including some strains of Escherichia coli responsible for urinary tract infections. The clinical significance varies according to the organism, infection site, resistance mechanism and available alternatives. Resistance can increase the probability that standard empirical treatment will be ineffective, potentially resulting in longer illness, additional testing, more complex treatment, hospitalisation or increased mortality in severe infections.
Antibiotic resistance also has an ecological dimension because antibiotics affect microbial populations beyond the pathogen causing the immediate infection. Antibiotic exposure can eliminate susceptible bacteria while leaving resistant organisms with a relative survival advantage. Resistant bacteria may then multiply or persist, and resistance genes can remain within microbial communities even after the immediate antibiotic course ends. Selection occurs in hospitals, communities, farms, wastewater systems, soil and other environments where bacteria, antibiotics and resistance genes can interact.
The term antimicrobial resistance is broader than antibiotic resistance: antimicrobial resistance includes resistance in bacteria, viruses, fungi and parasites to the drugs used against them. Antibiotic resistance specifically concerns bacteria and antibacterial drugs. This terminology matters because the mechanisms, treatments and public-health interventions differ between bacterial, viral, fungal and parasitic resistance.
Antibiotic resistance is influenced by antibiotic exposure but is not caused simply by one individual taking an antibiotic. Resistance is generated and selected at population level through a combination of bacterial evolution, horizontal gene transfer, antibiotic use, transmission between people and animals, environmental contamination and infection-control practices. Appropriate antibiotic use remains essential because withholding an antibiotic from a patient who genuinely has a serious bacterial infection can also be harmful.
Stewardship therefore does not mean avoiding antibiotics altogether; it means using them when indicated and choosing an effective, sufficiently targeted treatment while minimising unnecessary exposure. Vaccination, diagnostic testing, hygiene, infection prevention and control, surveillance and development of new antimicrobials all contribute to managing the problem.
The most useful way to understand antibiotic resistance is as a biological property that allows particular bacteria to withstand particular antibiotics, combined with an epidemiological process through which resistant organisms and resistance genes spread. It can arise through mutation or acquisition of resistance genes and can be amplified by selection when antibiotics eliminate susceptible competitors. Resistance may be narrowly specific or involve multiple drug classes.
Its consequences extend beyond one patient's treatment because resistant bacteria can spread to other people and environments. Effective management therefore requires both individual clinical decisions, such as appropriate prescribing and susceptibility-guided treatment, and population-level measures, including surveillance, infection prevention, vaccination, responsible antibiotic use in human and veterinary medicine, environmental controls and research into new therapies and diagnostic technologies.
